11025 North Torrey Pines Road
Suite 200 Torrey Pines Science Park
La Jolla, CA 92037
858 795 4220
|Mr. Mark Paul Lappe||Founder, Chairman, Pres & CEO||994,28k||N/A||1967|
|Dr. Brendan P. Eckelman Ph.D.||Founder & Chief Scientific Officer||644,5k||N/A||1979|
|Ms. Kelly Devine Deck B.S., CPA, M.S.||Exec. VP & CFO||423,75k||N/A||1981|
|Mr. Quinn L. Deveraux||Founder||N/A||N/A||N/A|
|Dr. Ashraf Amanullah||Exec. VP & Chief Technical Operations Officer||N/A||N/A||1968|
|Ms. Leah Pollema J.D.||VP, Corp. Sec. & Gen. Counsel||N/A||N/A||N/A|
|Dr. Charbel Helaihel Pharm.D.||VP of Marketing & Commercial Planning||N/A||N/A||N/A|
|Mr. Jeffrey J. Jensen||EVP & Chief Clinical Devel. Officer||N/A||N/A||N/A|
|Mr. David Matly M.B.A.||Exec. VP & Chief Commercial Officer||N/A||N/A||N/A|
|Dr. Carlos Bais Ph.D.||Exec. VP of Translational Sciences||N/A||N/A||N/A|
Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.
Inhibrx, Inc.s ISS Governance QualityScore, Stand 1. März 2023, lautet 9. Die grundlegenden Scores sind Audit: 6, Vorstand: 9, Shareholderrechte: 8, Kompensation: 8.